Madopark Depot (Benserazide Hydrochloride, Levodopa)

Madopark Depot is used in the dopaminergic pathway to treat Parkinsonian disorders.

• Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor.
• Parkinsonian syndrome: alleviates motor deficits associated with secondary Parkinsonism.
• Levodopa‑responsive Parkinsonism: provides symptomatic relief by restoring central dopamine levels.

• Levodopa is absorbed from the gastrointestinal tract and crosses the blood‑brain barrier, where aromatic L‑amino‑acid decarboxylase converts it to dopamine. Benserazide, a peripheral dopa‑decarboxylase inhibitor, blocks this conversion outside the brain, increasing the amount of levodopa that reaches central nervous system sites and reducing peripheral side effects.

Madopark Depot may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea and vomiting
• Dizziness or light‑headedness
• Orthostatic hypotension
• Headache
• Insomnia or vivid dreams
• Dry mouth

Serious or Rare Side Effects

• Dyskinesia (involuntary movements)
• Severe psychiatric disturbances (hallucinations, psychosis)
• Cardiac arrhythmias
• Neuroleptic malignant syndrome (very rare)
• Severe hypotension leading to syncope

When prescribing Madopark Depot, clinicians should consider several safety measures.

• Monitor for dyskinesia: adjust dose if involuntary movements appear.
• Assess cardiovascular status: watch for orthostatic hypotension and arrhythmias.
• Review concomitant MAO‑B inhibitors: avoid combined use due to hypertensive risk.
• Adjust dose in renal impairment: reduced clearance may increase plasma levels.
• Avoid abrupt discontinuation: taper gradually to prevent withdrawal symptoms.
• Store at room temperature: keep in the original pack, protect from moisture.

Madopark Depot can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis.
• Antipsychotics that block dopamine receptors (e.g., haloperidol): may reduce therapeutic effect.
• High‑protein meals taken concurrently: can diminish levodopa absorption.

Moderate Interactions (Monitor Closely)

• Sympathomimetic agents (e.g., epinephrine): may exacerbate hypertension.
• Antihypertensive drugs: additive blood‑pressure lowering effect.
• Selective serotonin reuptake inhibitors (SSRIs): monitor for serotonin syndrome signs.